The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval is backed by data showing deep, durable responses and manageable tolerability
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Subscribe To Our Newsletter & Stay Updated
